Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$3,675.00
Aug 12, 2025
For-profit organization
Canadian Life Sciences Co-Innovation Mission to Japan – October 2025
1034658
Participation in the Canadian Life Sciences co-innovation mission to Japan – October 6 to 10, 2025. Delegation led by the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to explore the Japanese market and to develop international partnerships and potential project ideas under the Japan Program. In Partnership with the Trade Commissioner Service Canadian Technology Accelerator (TCS CTA), and Deep Tech Canada, the Canadian delegation will also receive support for their international business and market-entry strategies, as well as get introductions to other potential partners and clients during the mission.
$500,000.00
Apr 1, 2025
For-profit organization
E!7296 COVANEXT: Unlocking druggability of disordered proteins
1028974
E!7296 COVANEXT: Unlocking druggability of disordered proteins
Co-International partner: Nuage Therapeutics SL, Spain
To advance the development of NT-A, a first-in-class covalent therapeutic for small cell lung cancer (SCLC).
$29,500.00
Jul 5, 2019
For-profit organization
Development of European markets for contract research services in drug discovery and development.
931389
To retain and further grow the R&D operations, Dalriada will expand its export into Germany and Switzerland, some of the top European life science industries.